IRADIMED Upgrades to NASDAQ Global Market

Iradimed Corporation, a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, has announced its uplisting to the NASDAQ Global Market, with trading set to commence on June 14, 2024. The company's common stock will continue under the ticker symbol "IRMD."

Roger Susi, President and CEO of Iradimed, expressed enthusiasm about the uplisting, noting that it reflects the company's continued growth trajectory and its dedication to delivering value to stockholders. He highlighted that the move to the NASDAQ Global Market will enhance Iradimed's visibility in the marketplace and expose it to a larger audience of potential new investors.

Iradimed was previously listed on the NASDAQ Capital Market following its successful initial public offering in 2014. The NASDAQ Global Market is known for its stringent financial and liquidity requirements and high corporate governance standards, and currently includes the common stock of approximately 1,450 companies.

Iradimed Corporation specializes in developing innovative MRI-compatible medical devices, including a non-magnetic intravenous (IV) infusion pump system designed for safe use during MRI procedures. The company's patented Mridium® MRI compatible IV infusion pump system, with its non-magnetic ultrasonic motor and uniquely designed non-ferrous parts, facilitates safe and predictable delivery of anesthesia and other IV fluids during various MRI procedures.

Furthermore, Iradimed's 3880 MRI-compatible patient vital signs monitoring system, designed with non-magnetic components and special features, allows for the safe and accurate monitoring of a patient's vital signs during MRI procedures. Operating dependably in magnetic fields up to 30,000 gauss, the system enables uninterrupted vital signs monitoring, enhancing patient safety and reducing the time critically ill patients are away from critical care units.

This uplisting to the NASDAQ Global Market marks a significant milestone for Iradimed Corporation, signaling its continued growth and commitment to providing innovative solutions for MRI-compatible medical devices. As a result of these announcements, the company's shares have moved -0.6% on the market, and are now trading at a price of $42.5. For the full picture, make sure to review IRADIMED CORPORATION's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.